TWI520740B - 利用多硫酸化多醣之骨髓水腫（水腫）的治療 - Google Patents
利用多硫酸化多醣之骨髓水腫（水腫）的治療 Download PDFInfo
- Publication number
- TWI520740B TWI520740B TW101103252A TW101103252A TWI520740B TW I520740 B TWI520740 B TW I520740B TW 101103252 A TW101103252 A TW 101103252A TW 101103252 A TW101103252 A TW 101103252A TW I520740 B TWI520740 B TW I520740B
- Authority
- TW
- Taiwan
- Prior art keywords
- polysulfate
- bone marrow
- treatment
- intra
- sulfate
- Prior art date
Links
- 206010051763 Bone marrow oedema Diseases 0.000 title claims description 67
- 150000004676 glycans Chemical class 0.000 title claims description 35
- 229920001282 polysaccharide Polymers 0.000 title claims description 35
- 239000005017 polysaccharide Substances 0.000 title claims description 35
- 238000011282 treatment Methods 0.000 title claims description 32
- 206010030113 Oedema Diseases 0.000 title description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 30
- 241000124008 Mammalia Species 0.000 claims description 27
- 239000007924 injection Substances 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 19
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 238000007918 intramuscular administration Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000829 suppository Substances 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 238000011285 therapeutic regimen Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 36
- 208000002193 Pain Diseases 0.000 description 23
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 22
- 210000000988 bone and bone Anatomy 0.000 description 16
- 229920000669 heparin Polymers 0.000 description 16
- 229960002897 heparin Drugs 0.000 description 16
- 230000006378 damage Effects 0.000 description 14
- 229920001661 Chitosan Polymers 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 208000014674 injury Diseases 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 239000003055 low molecular weight heparin Substances 0.000 description 10
- 229940127215 low-molecular weight heparin Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 201000008482 osteoarthritis Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 229940059329 chondroitin sulfate Drugs 0.000 description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Polymers O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 8
- 210000005065 subchondral bone plate Anatomy 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 208000034656 Contusions Diseases 0.000 description 5
- 229920000045 Dermatan sulfate Polymers 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- -1 pentosan polysulfate Chemical class 0.000 description 5
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 4
- 206010018735 Groin pain Diseases 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 4
- 229940051593 dermatan sulfate Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 210000004061 pubic symphysis Anatomy 0.000 description 4
- 206010066251 Bone contusion Diseases 0.000 description 3
- 208000017234 Bone cyst Diseases 0.000 description 3
- 229920002567 Chondroitin Polymers 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010064269 Bone marrow oedema syndrome Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000022120 Jeavons syndrome Diseases 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 206010031149 Osteitis Diseases 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 208000018339 bone inflammation disease Diseases 0.000 description 2
- 231100001018 bone marrow damage Toxicity 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940043138 pentosan polysulfate Drugs 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NBTMNFYXJYCQHQ-UHFFFAOYSA-N (2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate Chemical compound OS(=O)(=O)OC1C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C1OS(O)(=O)=O NBTMNFYXJYCQHQ-UHFFFAOYSA-N 0.000 description 1
- GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 description 1
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical class C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000025674 Anterior Cruciate Ligament injury Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000010300 Genu Varum Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010062061 Knee deformity Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920000439 Sulodexide Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003052 knee medial collateral ligament Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 210000001037 metacarpus Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 description 1
- 229960003491 sulodexide Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011900325A AU2011900325A0 (en) | 2011-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201309307A TW201309307A (zh) | 2013-03-01 |
| TWI520740B true TWI520740B (zh) | 2016-02-11 |
Family
ID=46602012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101103252A TWI520740B (zh) | 2011-02-02 | 2012-02-01 | 利用多硫酸化多醣之骨髓水腫（水腫）的治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9101650B2 (https=) |
| EP (1) | EP2670412B1 (https=) |
| JP (1) | JP5883458B2 (https=) |
| KR (1) | KR101840079B1 (https=) |
| CN (1) | CN103415293B (https=) |
| AU (1) | AU2012212398B2 (https=) |
| CA (1) | CA2826166C (https=) |
| DK (1) | DK2670412T3 (https=) |
| ES (1) | ES2664611T3 (https=) |
| MY (1) | MY164728A (https=) |
| NO (1) | NO2670412T3 (https=) |
| PT (1) | PT2670412T (https=) |
| SG (1) | SG192238A1 (https=) |
| TW (1) | TWI520740B (https=) |
| WO (1) | WO2012103588A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2926888C (en) * | 2013-10-22 | 2020-03-24 | Cell Receptor Sa | Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation |
| WO2019023761A1 (en) * | 2017-08-04 | 2019-02-07 | Paradigm Biopharmaceuticals Ltd | TREATMENT OF MEDICAL PATHOLOGIES WITH POLYSULFATED POLYSACCHARIDES |
| EP3813849A4 (en) | 2018-02-16 | 2021-12-08 | Proteobioactives Pty Limited | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION |
| US11701382B2 (en) | 2018-02-28 | 2023-07-18 | Paradigm Biopharmaceuticals Ltd | Treatment of post-operative joint pain with polysulfated polysaccharides |
| EP3863647B1 (en) * | 2018-10-10 | 2024-02-14 | Paradigm Biopharmaceuticals Limited | Treatment of malignant bone pain with pentosan polysulfate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| US6593310B1 (en) | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
| US6564083B2 (en) * | 2000-12-18 | 2003-05-13 | Hoffmann-La Roche Inc. | Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis |
| DE10225551A1 (de) * | 2002-06-06 | 2003-12-24 | Schering Ag | Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind |
| JP5542686B2 (ja) * | 2007-12-04 | 2014-07-09 | プロテオバイオアクティブズ・ピーティーワイ・リミテッド | 前駆細胞の保護およびその分化の調節 |
-
2012
- 2012-02-01 TW TW101103252A patent/TWI520740B/zh active
- 2012-02-02 SG SG2013058268A patent/SG192238A1/en unknown
- 2012-02-02 PT PT127415602T patent/PT2670412T/pt unknown
- 2012-02-02 ES ES12741560.2T patent/ES2664611T3/es active Active
- 2012-02-02 WO PCT/AU2012/000091 patent/WO2012103588A1/en not_active Ceased
- 2012-02-02 JP JP2013552065A patent/JP5883458B2/ja active Active
- 2012-02-02 EP EP12741560.2A patent/EP2670412B1/en active Active
- 2012-02-02 MY MYPI2013701355A patent/MY164728A/en unknown
- 2012-02-02 AU AU2012212398A patent/AU2012212398B2/en active Active
- 2012-02-02 CN CN201280007433.9A patent/CN103415293B/zh active Active
- 2012-02-02 CA CA2826166A patent/CA2826166C/en active Active
- 2012-02-02 DK DK12741560.2T patent/DK2670412T3/en active
- 2012-02-02 KR KR1020137022985A patent/KR101840079B1/ko active Active
- 2012-02-02 US US13/983,406 patent/US9101650B2/en active Active
- 2012-02-02 NO NO12741560A patent/NO2670412T3/no unknown
-
2015
- 2015-07-02 US US14/790,476 patent/US9861657B2/en active Active
-
2017
- 2017-09-29 US US15/720,884 patent/US10610542B2/en active Active
-
2020
- 2020-02-25 US US16/800,245 patent/US11406660B2/en active Active
-
2022
- 2022-07-05 US US17/857,420 patent/US20220362284A1/en not_active Abandoned
-
2023
- 2023-11-21 US US18/515,823 patent/US20240156858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2670412A4 (en) | 2015-07-08 |
| CA2826166A1 (en) | 2012-08-09 |
| MY164728A (en) | 2018-01-30 |
| DK2670412T3 (en) | 2018-03-12 |
| US20180021369A1 (en) | 2018-01-25 |
| US20220362284A1 (en) | 2022-11-17 |
| JP5883458B2 (ja) | 2016-03-15 |
| AU2012212398A1 (en) | 2013-09-19 |
| SG192238A1 (en) | 2013-09-30 |
| JP2014504613A (ja) | 2014-02-24 |
| EP2670412B1 (en) | 2018-01-03 |
| ES2664611T3 (es) | 2018-04-20 |
| CA2826166C (en) | 2017-05-09 |
| CN103415293B (zh) | 2016-08-10 |
| US10610542B2 (en) | 2020-04-07 |
| US20140024614A1 (en) | 2014-01-23 |
| TW201309307A (zh) | 2013-03-01 |
| NO2670412T3 (https=) | 2018-06-02 |
| US9861657B2 (en) | 2018-01-09 |
| KR101840079B1 (ko) | 2018-03-19 |
| US20210015849A1 (en) | 2021-01-21 |
| WO2012103588A1 (en) | 2012-08-09 |
| US9101650B2 (en) | 2015-08-11 |
| EP2670412A1 (en) | 2013-12-11 |
| US20150297633A1 (en) | 2015-10-22 |
| US20240156858A1 (en) | 2024-05-16 |
| US11406660B2 (en) | 2022-08-09 |
| AU2012212398B2 (en) | 2014-06-05 |
| CN103415293A (zh) | 2013-11-27 |
| KR20140012655A (ko) | 2014-02-03 |
| PT2670412T (pt) | 2018-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240156858A1 (en) | Treatment of Bone Marrow Edema (Oedema) With Polysulfated Polysaccharides | |
| Santos et al. | Cartilage lesions and ankle osteoarthrosis: review of the literature and treatment algorithm | |
| US12263187B2 (en) | Treatment of bone marrow pathologies with polysulfated polysaccharides | |
| Fattahi et al. | Investigating the Effect of Hyaluronic Acid on Pain Control in Total Ankle Arthroplasty: A systematic review | |
| Toy et al. | Corticosteroid, platelet-rich plasma, and ozone injections for sinus tarsi syndrome | |
| AU2019226627B2 (en) | Treatment of post-operative joint pain with polysulfated polysaccharides | |
| Gou et al. | Clinical Observation of Minimally Invasive Surgery and Conservative Treatment for Ankle Degenerative Osteoarthropathy | |
| Puri | Clinical study on the management of complex metaphyseal fractures of the tibia (proximal and distal) with hybrid external fixation |